Photo by nci from unsplash
RCHOP, HR 0.67 (95% CI 0.441.03), p (one-sided) =0.03 (Figure). The 2-year overall survival was 87% and 80%, respectively. Based on COO, PFS HR for R2CHOP was: 0.68 for ABC,… Click to show full abstract
RCHOP, HR 0.67 (95% CI 0.441.03), p (one-sided) =0.03 (Figure). The 2-year overall survival was 87% and 80%, respectively. Based on COO, PFS HR for R2CHOP was: 0.68 for ABC, p=0.15, 0.86 for GCB, 0.83 for Unclassified and 0.61 for unknown cases. Conclusion: The addition of lenalidomide to R-CHOP (R2CHOP) in this phase II study improved PFS in newly diagnosed DLBCL.
Keywords:
patients asymptomatic;
placebo patients;
versus placebo;
asymptomatic treatment;
ibrutinib versus;
treatment early
Journal Title: Hematological Oncology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Hematological Oncology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!